These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16293234)

  • 21. The melatonin analog 5-MCA-NAT increases endogenous dopamine levels by binding NRH:quinone reductase enzyme in the developing chick retina.
    Sampaio Lde F; Mesquita FP; de Sousa PR; Silva JL; Alves CN
    Int J Dev Neurosci; 2014 Nov; 38():119-26. PubMed ID: 25218627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antidote effect of quinone oxidoreductase 2 inhibitor against paraquat-induced toxicity in vitro and in vivo.
    Janda E; Parafati M; Aprigliano S; Carresi C; Visalli V; Sacco I; Ventrice D; Mega T; Vadalá N; Rinaldi S; Musolino V; Palma E; Gratteri S; Rotiroti D; Mollace V
    Br J Pharmacol; 2013 Jan; 168(1):46-59. PubMed ID: 22289031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melatonin inhibits granulocyte adhesion to ICAM via MT3/QR2 and MT2 receptors.
    Černyšiov V; Mauricas M; Girkontaite I
    Int Immunol; 2015 Dec; 27(12):599-608. PubMed ID: 26031343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
    Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
    Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors.
    Mathé-Allainmat M; Gaudy F; Sicsic S; Dangy-Caye AL; Shen S; Brémont B; Benatalah Z; Langlois M; Renard P; Delagrange P
    J Med Chem; 1996 Aug; 39(16):3089-95. PubMed ID: 8759629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.
    Ettaoussi M; Péres B; Klupsch F; Delagrange P; Boutin JA; Renard P; Caignard DH; Chavatte P; Berthelot P; Lesieur D; Yous S
    Bioorg Med Chem; 2008 May; 16(9):4954-62. PubMed ID: 18372181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three Australian Lepidosperma Labill. Species as sources of prenylated and oxyprenylated derivatives of piceatannol, resveratrol and pinosylvin: Melatoninergic binding and inhibition of quinone reductase 2.
    Hamid K; Tran VH; Duke RK; Duke CC
    Phytochemistry; 2022 Nov; 203():113396. PubMed ID: 35998831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.
    Poissonnier-Durieux S; Ettaoussi M; Pérès B; Boutin JA; Audinot V; Bennejean C; Delagrange P; Caignard DH; Renard P; Berthelot P; Lesieur D; Yous S
    Bioorg Med Chem; 2008 Sep; 16(18):8339-48. PubMed ID: 18778943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular tools to study melatonin pathways and actions.
    Boutin JA; Audinot V; Ferry G; Delagrange P
    Trends Pharmacol Sci; 2005 Aug; 26(8):412-9. PubMed ID: 15992934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is There Sufficient Evidence that the Melatonin Binding Site
    Boutin JA; Ferry G
    J Pharmacol Exp Ther; 2019 Jan; 368(1):59-65. PubMed ID: 30389722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs.
    Celli CM; Tran N; Knox R; Jaiswal AK
    Biochem Pharmacol; 2006 Jul; 72(3):366-76. PubMed ID: 16765324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties.
    Herrera-Arozamena C; Estrada-Valencia M; Pérez C; Lagartera L; Morales-García JA; Pérez-Castillo A; Franco-Gonzalez JF; Michalska P; Duarte P; León R; López MG; Mills A; Gago F; García-Yagüe ÁJ; Fernández-Ginés R; Cuadrado A; Rodríguez-Franco MI
    Eur J Med Chem; 2020 Mar; 190():112090. PubMed ID: 32018096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melatonergic properties of the (+)- and (-)-enantiomers of N-(4-methoxy-2,3-dihydro-1H-phenalen-2-yl)amide derivatives.
    Jellimann C; Mathé-Allainmat M; Andrieux J; Renard P; Delagrange P; Langlois M
    J Med Chem; 1999 Mar; 42(6):1100-5. PubMed ID: 10090792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal structure of human quinone reductase type 2, a metalloflavoprotein.
    Foster CE; Bianchet MA; Talalay P; Zhao Q; Amzel LM
    Biochemistry; 1999 Aug; 38(31):9881-6. PubMed ID: 10433694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measuring Binding at the Putative Melatonin Receptor MT3.
    Legros C; Dupuis P; Ferry G; Boutin JA
    Methods Mol Biol; 2022; 2550():283-289. PubMed ID: 36180699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinone reductase 2 substrate specificity and inhibition pharmacology.
    Boutin JA; Chatelain-Egger F; Vella F; Delagrange P; Ferry G
    Chem Biol Interact; 2005 Feb; 151(3):213-28. PubMed ID: 15733542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference.
    Chomarat P; Cogé F; Guénin SP; Mailliet F; Vella F; Mallet C; Giraudet S; Nagel N; Leonce S; Ferry G; Delagrange P; Boutin JA
    Biochimie; 2007 Oct; 89(10):1264-75. PubMed ID: 17714848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.
    Durieux S; Chanu A; Bochu C; Audinot V; Coumailleau S; Boutin JA; Delagrange P; Caignard DH; Bennejean C; Renard P; Lesieur D; Berthelot P; Yous S
    Bioorg Med Chem; 2009 Apr; 17(8):2963-74. PubMed ID: 19329323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of the melatonin-binding site MT3 as the quinone reductase 2.
    Nosjean O; Ferro M; Coge F; Beauverger P; Henlin JM; Lefoulon F; Fauchere JL; Delagrange P; Canet E; Boutin JA
    J Biol Chem; 2000 Oct; 275(40):31311-7. PubMed ID: 10913150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.